Review



ultimate splash lipidomics internal standard mixture  (Croda International Plc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Croda International Plc ultimate splash lipidomics internal standard mixture
    Ultimate Splash Lipidomics Internal Standard Mixture, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 95/100, based on 127 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lipidomic+splash/10__1016_slash_j__jcoa__2025__100295-57-0-9?v=Croda+International+Plc
    Average 95 stars, based on 127 article reviews
    ultimate splash lipidomics internal standard mixture - by Bioz Stars, 2026-08
    95/100 stars

    Images



    Similar Products

    ultimate splash lipidomics internal standard mixture  (Croda International Plc)
    95
    Croda International Plc ultimate splash lipidomics internal standard mixture
    Ultimate Splash Lipidomics Internal Standard Mixture, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lipidomic+splash/10__1016_slash_j__jcoa__2025__100295-57-0-9?v=Croda+International+Plc
    Average 95 stars, based on 1 article reviews
    ultimate splash lipidomics internal standard mixture - by Bioz Stars, 2026-08
    95/100 stars
    		  Buy from Supplier
    splash lipidomix mass spec standard  (Avanti Polar)
    91
    Avanti Polar splash lipidomix mass spec standard
    Splash Lipidomix Mass Spec Standard, supplied by Avanti Polar, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lipidomic+splash/custom%40330707%4010%2E1101%2F2025%2E09%2E21%2E676806?v=Avanti+Polar
    Average 91 stars, based on 1 article reviews
    splash lipidomix mass spec standard - by Bioz Stars, 2026-08
    91/100 stars
    		  Buy from Supplier
    splashmix lipidomic mass 267 spec standard  (Croda International Plc)
    91
    Croda International Plc splashmix lipidomic mass 267 spec standard
    Splashmix Lipidomic Mass 267 Spec Standard, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lipidomic+splash/pmc10919283__bi3c00647_si_001-134-29-35?v=Croda+International+Plc
    Average 91 stars, based on 1 article reviews
    splashmix lipidomic mass 267 spec standard - by Bioz Stars, 2026-08
    91/100 stars
    		  Buy from Supplier
    splash lipidomics standard  (Croda International Plc)
    91
    Croda International Plc splash lipidomics standard
    a Schmatic representation of sampling and analysis of our Cohort of 38 T2D patients and 39 age and sex-matched healthy controls. Plasma and skin punch biopsies were analysed with an LC-MS/MS based untargeted <t>lipidomics</t> and proteomics as well as in a targeted metabolomics approach. b Volcano plot showing lipidomics data of T2D diabetic skin compared to healthy controls (cutoff |log2FC| ≥ 0.75, p-value ≤ 0.05). 1-deoxySL (red) and canonical SL (blue) are indicated. c Total skin 1-deoxyDHCer (m18:0) and 1-deoxyCer (m18:1) per 10mg of wet tissue. Data are represented individually and as mean ± SD. P-values indicate the significance of the group comparisons (two-way Student’s unpaired t-test); *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001. d Principal component analysis (PCA) of the skin proteome (2,309 quantified proteins) shows a distinct clustering between T2D and control groups, indicating disease-specific proteomic signatures. e Volcano plot showing proteomics data of T2D skin (N=38) compared to healthy controls (N=39). Cutoffs: log2FC ≥ 0.75, q-value ≤ 0.05. Proteins enriched (red) and reduced (blue) in T2D skin are indicated. Proteasomal proteins are represented in green, neuronal proteins in orange. f STRING analysis of the upregulated proteins in the skin of T2D. The highest confidence interval of interaction (0.9) was applied. Subsequently, MCL clustering (inflation parameter=3) was used. Clusters were colored using the KEGG database. g Gene set enrichment analysis (GSEA) based on log2FC values from differential analysis of the skin proteomics between T2D patients (N=38) and healthy controls (N=39). Pathways were parsed by the KEGG database.
    Splash Lipidomics Standard, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lipidomic+splash/bio_rxiv__2025__04__25__650588-301-74-78?v=Croda+International+Plc
    Average 91 stars, based on 1 article reviews
    splash lipidomics standard - by Bioz Stars, 2026-08
    91/100 stars
    		  Buy from Supplier
    splash lipidmix lipidomic mass spectrometry standards  (Croda International Plc)
    91
    Croda International Plc splash lipidmix lipidomic mass spectrometry standards
    a Schmatic representation of sampling and analysis of our Cohort of 38 T2D patients and 39 age and sex-matched healthy controls. Plasma and skin punch biopsies were analysed with an LC-MS/MS based untargeted <t>lipidomics</t> and proteomics as well as in a targeted metabolomics approach. b Volcano plot showing lipidomics data of T2D diabetic skin compared to healthy controls (cutoff |log2FC| ≥ 0.75, p-value ≤ 0.05). 1-deoxySL (red) and canonical SL (blue) are indicated. c Total skin 1-deoxyDHCer (m18:0) and 1-deoxyCer (m18:1) per 10mg of wet tissue. Data are represented individually and as mean ± SD. P-values indicate the significance of the group comparisons (two-way Student’s unpaired t-test); *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001. d Principal component analysis (PCA) of the skin proteome (2,309 quantified proteins) shows a distinct clustering between T2D and control groups, indicating disease-specific proteomic signatures. e Volcano plot showing proteomics data of T2D skin (N=38) compared to healthy controls (N=39). Cutoffs: log2FC ≥ 0.75, q-value ≤ 0.05. Proteins enriched (red) and reduced (blue) in T2D skin are indicated. Proteasomal proteins are represented in green, neuronal proteins in orange. f STRING analysis of the upregulated proteins in the skin of T2D. The highest confidence interval of interaction (0.9) was applied. Subsequently, MCL clustering (inflation parameter=3) was used. Clusters were colored using the KEGG database. g Gene set enrichment analysis (GSEA) based on log2FC values from differential analysis of the skin proteomics between T2D patients (N=38) and healthy controls (N=39). Pathways were parsed by the KEGG database.
    Splash Lipidmix Lipidomic Mass Spectrometry Standards, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lipidomic+splash/bio_rxiv__2025__03__31__646481-348-0-6?v=Croda+International+Plc
    Average 91 stars, based on 1 article reviews
    splash lipidmix lipidomic mass spectrometry standards - by Bioz Stars, 2026-08
    91/100 stars
    		  Buy from Supplier
    splash lipidomics internal standard mix  (Croda International Plc)
    95
    Croda International Plc splash lipidomics internal standard mix
    a Schmatic representation of sampling and analysis of our Cohort of 38 T2D patients and 39 age and sex-matched healthy controls. Plasma and skin punch biopsies were analysed with an LC-MS/MS based untargeted <t>lipidomics</t> and proteomics as well as in a targeted metabolomics approach. b Volcano plot showing lipidomics data of T2D diabetic skin compared to healthy controls (cutoff |log2FC| ≥ 0.75, p-value ≤ 0.05). 1-deoxySL (red) and canonical SL (blue) are indicated. c Total skin 1-deoxyDHCer (m18:0) and 1-deoxyCer (m18:1) per 10mg of wet tissue. Data are represented individually and as mean ± SD. P-values indicate the significance of the group comparisons (two-way Student’s unpaired t-test); *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001. d Principal component analysis (PCA) of the skin proteome (2,309 quantified proteins) shows a distinct clustering between T2D and control groups, indicating disease-specific proteomic signatures. e Volcano plot showing proteomics data of T2D skin (N=38) compared to healthy controls (N=39). Cutoffs: log2FC ≥ 0.75, q-value ≤ 0.05. Proteins enriched (red) and reduced (blue) in T2D skin are indicated. Proteasomal proteins are represented in green, neuronal proteins in orange. f STRING analysis of the upregulated proteins in the skin of T2D. The highest confidence interval of interaction (0.9) was applied. Subsequently, MCL clustering (inflation parameter=3) was used. Clusters were colored using the KEGG database. g Gene set enrichment analysis (GSEA) based on log2FC values from differential analysis of the skin proteomics between T2D patients (N=38) and healthy controls (N=39). Pathways were parsed by the KEGG database.
    Splash Lipidomics Internal Standard Mix, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lipidomic+splash/10__70401_slash_fos__2025__0003-141-10-15?v=Croda+International+Plc
    Average 95 stars, based on 1 article reviews
    splash lipidomics internal standard mix - by Bioz Stars, 2026-08
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    a Schmatic representation of sampling and analysis of our Cohort of 38 T2D patients and 39 age and sex-matched healthy controls. Plasma and skin punch biopsies were analysed with an LC-MS/MS based untargeted lipidomics and proteomics as well as in a targeted metabolomics approach. b Volcano plot showing lipidomics data of T2D diabetic skin compared to healthy controls (cutoff |log2FC| ≥ 0.75, p-value ≤ 0.05). 1-deoxySL (red) and canonical SL (blue) are indicated. c Total skin 1-deoxyDHCer (m18:0) and 1-deoxyCer (m18:1) per 10mg of wet tissue. Data are represented individually and as mean ± SD. P-values indicate the significance of the group comparisons (two-way Student’s unpaired t-test); *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001. d Principal component analysis (PCA) of the skin proteome (2,309 quantified proteins) shows a distinct clustering between T2D and control groups, indicating disease-specific proteomic signatures. e Volcano plot showing proteomics data of T2D skin (N=38) compared to healthy controls (N=39). Cutoffs: log2FC ≥ 0.75, q-value ≤ 0.05. Proteins enriched (red) and reduced (blue) in T2D skin are indicated. Proteasomal proteins are represented in green, neuronal proteins in orange. f STRING analysis of the upregulated proteins in the skin of T2D. The highest confidence interval of interaction (0.9) was applied. Subsequently, MCL clustering (inflation parameter=3) was used. Clusters were colored using the KEGG database. g Gene set enrichment analysis (GSEA) based on log2FC values from differential analysis of the skin proteomics between T2D patients (N=38) and healthy controls (N=39). Pathways were parsed by the KEGG database.

    Journal: bioRxiv

    Article Title: Metabolic Origins of Neurotoxic 1-deoxySphingolipids in Type 2 Diabetes

    doi: 10.1101/2025.04.25.650588

    Figure Lengend Snippet: a Schmatic representation of sampling and analysis of our Cohort of 38 T2D patients and 39 age and sex-matched healthy controls. Plasma and skin punch biopsies were analysed with an LC-MS/MS based untargeted lipidomics and proteomics as well as in a targeted metabolomics approach. b Volcano plot showing lipidomics data of T2D diabetic skin compared to healthy controls (cutoff |log2FC| ≥ 0.75, p-value ≤ 0.05). 1-deoxySL (red) and canonical SL (blue) are indicated. c Total skin 1-deoxyDHCer (m18:0) and 1-deoxyCer (m18:1) per 10mg of wet tissue. Data are represented individually and as mean ± SD. P-values indicate the significance of the group comparisons (two-way Student’s unpaired t-test); *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001. d Principal component analysis (PCA) of the skin proteome (2,309 quantified proteins) shows a distinct clustering between T2D and control groups, indicating disease-specific proteomic signatures. e Volcano plot showing proteomics data of T2D skin (N=38) compared to healthy controls (N=39). Cutoffs: log2FC ≥ 0.75, q-value ≤ 0.05. Proteins enriched (red) and reduced (blue) in T2D skin are indicated. Proteasomal proteins are represented in green, neuronal proteins in orange. f STRING analysis of the upregulated proteins in the skin of T2D. The highest confidence interval of interaction (0.9) was applied. Subsequently, MCL clustering (inflation parameter=3) was used. Clusters were colored using the KEGG database. g Gene set enrichment analysis (GSEA) based on log2FC values from differential analysis of the skin proteomics between T2D patients (N=38) and healthy controls (N=39). Pathways were parsed by the KEGG database.

    Article Snippet: List of internal standards: D5-1-desoxymethylsphinganine (m17:0, 860476, Avanti Polar Lipids) 100pmol/sample D7-Sphinganine (d18:0, 860658, Avanti Polar Lipids) 100pmol/sample D7-Sphingosine (d18:1, 860657, Avanti Polar Lipids) 100pmol/sample D7-Sphingosine-1-phosphate (d18:1, 860659, Avanti Polar Lipids) 50pmol/sample 1-deoxydihydroceramide (m18:0/12:0, 860460P, Avanti Polar Lipids) 100pmol/sample 1-deoxyceramide (m18:1/12:0, 860455, Avanti Polar Lipids) 100pmol/sample Dihydroceramide (d18:0/12:0, 860635, Avanti Polar Lipids) 100pmol/sample Ceramide (d18:1/12:0, 860512, Avanti Polar Lipids) 100pmol/sample SM (d18:1/12:0, 860583, Avanti Polar Lipids) 100pmol/sample Glucosylceramide (d18:1/8:0, 860540, Avanti Polar Lipids) 100pmol/sample SPLASH lipidomics standard (330707, Avanti Polar Lipids) 2.5µL/sample Dilutions of pooled quality control samples (QC 100%, QC 75%, QC 50%, QC 25%, QC 10%) were analysed regularly during the measurement.

    Techniques: Sampling, Clinical Proteomics, Liquid Chromatography with Mass Spectroscopy, Control

    a Violin plots showing skin amino acid levels in T2D (N=38) and healthy controls (N=39). Glycine (Gly), Glutamate (Glu), Arginine (Arg), Aspartate (Asp), Isoleucine (Ile), Leucine (Leu), Lysine (Lys), Methionine (Met), Phenylalanine (Phe), Proline (Pro), Threonine (Thr), Tyrosine (Tyr), Valine (Val) were measured using targeted LC-MS/MS metabolomics. Statistical significance was tested using Mann-Whitney and corrected for multiple testing using a two stages step-up method (Benjamini, Krieger and Yekutieli) b L-Alanine to L-Serine ratio (ala/ser) in skin tissue of T2D (N=38) compared to healthy controls (N=39). p reflects the significance of the group comparisons (Student’s unpaired t-test, ****=p<0.0001) c Correlation of plasma 1-deoxySL/SL and skin 1-deoxySL/SL. All correlations are represented as Pearson Correlation coefficient calculated from the whole cohort (N=77, red T2D, blue Controls). d Sphingolipidomics analysis of human plasma High density (HDL) and Low density lipoproteins (LDL). Lipoproteins were isolated from healthy donors and analyzed using untargeted LC- MS/MS lipidomics as described. e Amino acid and f Sphingolipidomics analysis of 6 and 12 weeks old, db/db (dbdb, N=10 and N=10, respectively) or db/+ (dbplus, N=10 and N=9, respectively) mouse liver tissue samples g Sphingolipidomics analysis of 6 and 12 weeks old, db/db (dbdb) or db/+ (dbplus) liver tissues and corresponding mouse plasma samples. h Correlation of liver and plasma 1-deoxySL/SL in dbdb mice. i Amino acid and j Sphingolipidomics analysis of 6 weeks old streptozotocin (STZ, N=15) or Vehicle (N=10) treated rat liver samples. k Sphingolipidomics analysis of 6 weeks old streptozotocin (STZ, N=15) or Vehicle (N=10) treated rat plasma samples. l Correlation of 1-deoxySL/SL in liver and plasma of the STZ rat vs control.

    Journal: bioRxiv

    Article Title: Metabolic Origins of Neurotoxic 1-deoxySphingolipids in Type 2 Diabetes

    doi: 10.1101/2025.04.25.650588

    Figure Lengend Snippet: a Violin plots showing skin amino acid levels in T2D (N=38) and healthy controls (N=39). Glycine (Gly), Glutamate (Glu), Arginine (Arg), Aspartate (Asp), Isoleucine (Ile), Leucine (Leu), Lysine (Lys), Methionine (Met), Phenylalanine (Phe), Proline (Pro), Threonine (Thr), Tyrosine (Tyr), Valine (Val) were measured using targeted LC-MS/MS metabolomics. Statistical significance was tested using Mann-Whitney and corrected for multiple testing using a two stages step-up method (Benjamini, Krieger and Yekutieli) b L-Alanine to L-Serine ratio (ala/ser) in skin tissue of T2D (N=38) compared to healthy controls (N=39). p reflects the significance of the group comparisons (Student’s unpaired t-test, ****=p<0.0001) c Correlation of plasma 1-deoxySL/SL and skin 1-deoxySL/SL. All correlations are represented as Pearson Correlation coefficient calculated from the whole cohort (N=77, red T2D, blue Controls). d Sphingolipidomics analysis of human plasma High density (HDL) and Low density lipoproteins (LDL). Lipoproteins were isolated from healthy donors and analyzed using untargeted LC- MS/MS lipidomics as described. e Amino acid and f Sphingolipidomics analysis of 6 and 12 weeks old, db/db (dbdb, N=10 and N=10, respectively) or db/+ (dbplus, N=10 and N=9, respectively) mouse liver tissue samples g Sphingolipidomics analysis of 6 and 12 weeks old, db/db (dbdb) or db/+ (dbplus) liver tissues and corresponding mouse plasma samples. h Correlation of liver and plasma 1-deoxySL/SL in dbdb mice. i Amino acid and j Sphingolipidomics analysis of 6 weeks old streptozotocin (STZ, N=15) or Vehicle (N=10) treated rat liver samples. k Sphingolipidomics analysis of 6 weeks old streptozotocin (STZ, N=15) or Vehicle (N=10) treated rat plasma samples. l Correlation of 1-deoxySL/SL in liver and plasma of the STZ rat vs control.

    Article Snippet: List of internal standards: D5-1-desoxymethylsphinganine (m17:0, 860476, Avanti Polar Lipids) 100pmol/sample D7-Sphinganine (d18:0, 860658, Avanti Polar Lipids) 100pmol/sample D7-Sphingosine (d18:1, 860657, Avanti Polar Lipids) 100pmol/sample D7-Sphingosine-1-phosphate (d18:1, 860659, Avanti Polar Lipids) 50pmol/sample 1-deoxydihydroceramide (m18:0/12:0, 860460P, Avanti Polar Lipids) 100pmol/sample 1-deoxyceramide (m18:1/12:0, 860455, Avanti Polar Lipids) 100pmol/sample Dihydroceramide (d18:0/12:0, 860635, Avanti Polar Lipids) 100pmol/sample Ceramide (d18:1/12:0, 860512, Avanti Polar Lipids) 100pmol/sample SM (d18:1/12:0, 860583, Avanti Polar Lipids) 100pmol/sample Glucosylceramide (d18:1/8:0, 860540, Avanti Polar Lipids) 100pmol/sample SPLASH lipidomics standard (330707, Avanti Polar Lipids) 2.5µL/sample Dilutions of pooled quality control samples (QC 100%, QC 75%, QC 50%, QC 25%, QC 10%) were analysed regularly during the measurement.

    Techniques: Liquid Chromatography with Mass Spectroscopy, MANN-WHITNEY, Clinical Proteomics, Isolation, Control

    a Schematic overview of serine biosynthetic and catabolic pathways. b UC13Glucose to SL tracing in PHGDH knockout (PHGDH KO) HEK293 cells. c-e UC13Glucose to SL tracing complemented with D3N15Serine, D4Alanine or 3-phosphoglycerate (3PG) supplementation. Total 1-deoxySL+2C13 (c), Total canonical SL+2C13 (d), 2C13doxSL/2C13SL (e), 1-deoxySL+D3 (supplemented d4Alanine derived, f), SL+D2N15 (supplemented D3N15Serine derived, f-h Overexpression of serine-degrading enzymes, Serine dehydratase (SDS) and alanine-glyoxylate aminotransferase (AGXT) or empty vector (EV) in HEK293 cells, combined with UC13Glucose to SL tracing. h Influence of SDS, AGXT or EV overexpression in HEK293 cells on D4Alanine derived 1-deoxySL+D3 and D3N15Serine derived canonical SL+D2N15 as well as the ratio between 1-deoxySL/SL. i siRNA mediated knockdown of SDS in HEK293 cells coupled with UC13Glucose to SL tracing. j siRNA mediated knockdown of AGXT in HEK293 cells coupled with UC13Glucose to SL tracing. k Effect of inhibiting the Mitochondrial Pyruvate carrier protein (MPC) by UK5099 or by uncoupling OxPhos with FCCP on the UC13Glucose to SL flux in Huh7 cells. l Influence of FCCP treatment on intracellular L-ala and L-ser concentrations in differentiated C2C12 myotubes. All lipids and metabolites were quantified using high resolution LC- MS/MS as indicated in the methods sections. m Scheme illustrating experiment with L-Serine supplementation on STZ treated Rats. n Liver 1-deoxySL/SL ratio in Vehicle, STZ or STZ + L-Serine treated rats. Lipids were measured by high resolution LC-MS/MS lipidomics as described in method section. All data are represented as mean ± SD. P-values indicate the significance of difference between the groups (two-way Student’s unpaired t-test); *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001

    Journal: bioRxiv

    Article Title: Metabolic Origins of Neurotoxic 1-deoxySphingolipids in Type 2 Diabetes

    doi: 10.1101/2025.04.25.650588

    Figure Lengend Snippet: a Schematic overview of serine biosynthetic and catabolic pathways. b UC13Glucose to SL tracing in PHGDH knockout (PHGDH KO) HEK293 cells. c-e UC13Glucose to SL tracing complemented with D3N15Serine, D4Alanine or 3-phosphoglycerate (3PG) supplementation. Total 1-deoxySL+2C13 (c), Total canonical SL+2C13 (d), 2C13doxSL/2C13SL (e), 1-deoxySL+D3 (supplemented d4Alanine derived, f), SL+D2N15 (supplemented D3N15Serine derived, f-h Overexpression of serine-degrading enzymes, Serine dehydratase (SDS) and alanine-glyoxylate aminotransferase (AGXT) or empty vector (EV) in HEK293 cells, combined with UC13Glucose to SL tracing. h Influence of SDS, AGXT or EV overexpression in HEK293 cells on D4Alanine derived 1-deoxySL+D3 and D3N15Serine derived canonical SL+D2N15 as well as the ratio between 1-deoxySL/SL. i siRNA mediated knockdown of SDS in HEK293 cells coupled with UC13Glucose to SL tracing. j siRNA mediated knockdown of AGXT in HEK293 cells coupled with UC13Glucose to SL tracing. k Effect of inhibiting the Mitochondrial Pyruvate carrier protein (MPC) by UK5099 or by uncoupling OxPhos with FCCP on the UC13Glucose to SL flux in Huh7 cells. l Influence of FCCP treatment on intracellular L-ala and L-ser concentrations in differentiated C2C12 myotubes. All lipids and metabolites were quantified using high resolution LC- MS/MS as indicated in the methods sections. m Scheme illustrating experiment with L-Serine supplementation on STZ treated Rats. n Liver 1-deoxySL/SL ratio in Vehicle, STZ or STZ + L-Serine treated rats. Lipids were measured by high resolution LC-MS/MS lipidomics as described in method section. All data are represented as mean ± SD. P-values indicate the significance of difference between the groups (two-way Student’s unpaired t-test); *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001

    Article Snippet: List of internal standards: D5-1-desoxymethylsphinganine (m17:0, 860476, Avanti Polar Lipids) 100pmol/sample D7-Sphinganine (d18:0, 860658, Avanti Polar Lipids) 100pmol/sample D7-Sphingosine (d18:1, 860657, Avanti Polar Lipids) 100pmol/sample D7-Sphingosine-1-phosphate (d18:1, 860659, Avanti Polar Lipids) 50pmol/sample 1-deoxydihydroceramide (m18:0/12:0, 860460P, Avanti Polar Lipids) 100pmol/sample 1-deoxyceramide (m18:1/12:0, 860455, Avanti Polar Lipids) 100pmol/sample Dihydroceramide (d18:0/12:0, 860635, Avanti Polar Lipids) 100pmol/sample Ceramide (d18:1/12:0, 860512, Avanti Polar Lipids) 100pmol/sample SM (d18:1/12:0, 860583, Avanti Polar Lipids) 100pmol/sample Glucosylceramide (d18:1/8:0, 860540, Avanti Polar Lipids) 100pmol/sample SPLASH lipidomics standard (330707, Avanti Polar Lipids) 2.5µL/sample Dilutions of pooled quality control samples (QC 100%, QC 75%, QC 50%, QC 25%, QC 10%) were analysed regularly during the measurement.

    Techniques: Knock-Out, Derivative Assay, Over Expression, Plasmid Preparation, Knockdown, Liquid Chromatography with Mass Spectroscopy